Johnson Investment Counsel’s Cymabay Therapeutics CBAY Stock Holding History

Johnson Investment Counsel’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,000	Closed	-$197K	–	716
2023 Q2	$197K	Hold	18,000	–	–	﹤0.01%	642
2023 Q1	$157K	Hold	18,000	–	–	﹤0.01%	640
2022 Q4	$113K	Hold	18,000	–	–	﹤0.01%	645
2022 Q3	$63K	Hold	18,000	–	–	﹤0.01%	638
2022 Q2	$53K	Hold	18,000	–	–	﹤0.01%	644
2022 Q1	$56K	Hold	18,000	–	–	﹤0.01%	664
2021 Q4	$61K	Hold	18,000	–	–	﹤0.01%	663
2021 Q3	$66K	Hold	18,000	–	–	﹤0.01%	646
2021 Q2	$78K	Hold	18,000	–	–	﹤0.01%	628
2021 Q1	$82K	Hold	18,000	–	–	﹤0.01%	596
2020 Q4	$103K	Buy	+18,000	New	+$136K	﹤0.01%	582

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Johnson Investment Counsel's CBAY Position: Q3 2023 in Review

Johnson Investment Counsel sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 18,000 shares — an estimated $197K sold.

Johnson Investment Counsel first reported a position in CBAY in Q4 2020 and held it in 11 quarters. The position peaked at $197K in Q2 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

Johnson Investment Counsel reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
Johnson Investment Counsel sold 18,000 Cymabay Therapeutics shares in Q3 2023, an estimated $197K.
Johnson Investment Counsel first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 11 quarters.
Johnson Investment Counsel's Cymabay Therapeutics position peaked at $197K in Q2 2023.
189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Johnson Investment Counsel's 13F filing for Q3 2023, filed 13 Nov 2023.